Advances in diagnosis and treatment of eosinophilia

Current Opinion in Hematology

Volumn 16, Issue 1, 2009, Pages 3-8

  Sheikh, Javed ^a,b   Weller, Peter F ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chronic eosinophilic leukemia; Eosinophilia; Eosinophils; Hypereosinophilic syndrome; Imatinib

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CD5 ANTIGEN; CYANOCOBALAMIN; CYCLOSPORIN A; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 5; MEPOLIZUMAB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; T LYMPHOCYTE RECEPTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FIP1L1; TROPONIN; TRYPTASE; UNCLASSIFIED DRUG;

ANEMIA; ANTIGEN EXPRESSION; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CELL CLONE; CELL POPULATION; CELL SUBPOPULATION; CHROMOSOME 4Q; CHROMOSOME DELETION; CHROMOSOME MUTATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG RESPONSE; ENZYME BLOOD LEVEL; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEPATOSPLENOMEGALY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTIC HYPEREOSINOPHILIC SYNDROME; MOLECULAR GENETICS; MYELOFIBROSIS; MYELOPROLIFERATIVE HYPEREOSINOPHILIC SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THROMBOCYTOPENIA; VITAMIN BLOOD LEVEL;

DIAGNOSIS, COMPUTER-ASSISTED; EOSINOPHILIA; HUMANS; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE DISORDERS; MYELOPROLIFERATIVE DISORDERS;

EID: 58149127252     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32831c841f     Document Type: Review

References (44)

1. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759-2779.
2. Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000; 7:21-25.
3. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003; 54:169-184.
4. Klion AD, Bochner BS, Gleich GJ, et al. The hypereosinophilic syndromes working group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117:1292-1302.
5. Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:333-355.
6. Spry C. Eosinophils. A comprehensive review and guide to the scientific and medical literature. Oxford, UK: Oxford Medical Publications; 1988.
7. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54:1-27.
8. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968; 68:1220-1229.
9. Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 1989; 140:253-257.
10. Spry CJ, Davies J, Tai PC, et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983; 52:1-22.
11. Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97:78-92.
12. Katz HT, Haque SJ, Hsieh FH. Pediatric hypereosinophilic syndrome (HES) differs from adult HES. J Pediatr 2005; 146:134-136.
13. Rives S, Alcorta I, Toll T, et al. Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement. J Pediatr Hematol Oncol 2005; 27:663-665.
14. Roufosse F, Goldman M, Cogan E. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med 2006; 27:158-170.
15. Ackerman GA. Eosinophilic leukemia: a morphologic and histochemical study. Blood 1964; 24:372-388.
16. Dale DC, Hubert RT, Fauci A. Eosinophil kinetics in the hypereosinophilic syndrome. J Lab Clin Med 1976; 87:487-495.
17. Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981; 58:1021-1026.
18. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201-1214.
19. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 2004; 77:82-85.
20. Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007; 27:377-388. An excellent review of the contemporary thinking of overlap between chronic eosinophilic leukemias and HES, with particular attention on the FIP1L1 -PDGFRα mutation positive variant of M-HES.
21. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660-4666.
22. Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007; 27: 357-375.
23. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104:3038-3045.
24. Raghavachar A, Fleischer S, Frickhofen N, et al. T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol 1987; 139:3753-3758.
25. Schrezenmeier H, Thome SD, Tewald F, et al. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome. Exp Hematol 1993; 21:358-365.
26. Cogan E, Schandene L, Crusiaux A, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994; 330:535-538.
27. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59:673-689.
28. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112-1120.
29. Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000; 109:540-548.
30. Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003; 100:7830-7835.
31. Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:457-475. Comprehensive review of the forms of cardiovascular involvement in HES, with discussion of implications for therapy.
32. Gertz MA. Troponin in hematologic oncology. Leuk Lymphoma 2008; 49:194-203. This is the first review to discuss the role of measurement of troponin level in blood to assess myocardial involvement in HES.
33. Klion AD. Approach to the therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:551-560.
34. Simon HU, Cools J. Novel approaches to therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:519-527.
35. Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007; 110:3552-3556. One of the first studies to discuss optimal dosing of imatinib for FIP1L1/PDGFRA-positive CEL/HES, which will likely lead to further studies along these lines.
36. Helbig G, Stella-Holowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008; 141:200-204.
37. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103:473-478.
38. Schandene L, Del Prete GF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest 1996; 97:309-315.
39. Schandene L, Roufosse F, de Lavareille A, et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 2000; 96:4285-4292.
40. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2007; 2:37.
41. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358:1215-1228. Report of the most comprehensive study of a monoclonal antibody to IL-5, which describes efficacy as a steroid-sparing agent for non FIP1L1/PDGFRA HES.
42. Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008; 121:1473-1483; 1483 e1471-1474. A groundbreaking study, shedding light on the mechanisms of action and efficacy of this monoclonal antibody to IL-5.
43. Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004; 127:477.
44. Sefcick A, Sowter D, DasGupta E, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004; 124:558-559.